FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4254366380> ?p ?o ?g. }

• W4254366380 abstract "Radiotherapy has been proposed as a treatment for new vessel growth in people with neovascular age-related macular degeneration (AMD).To examine the effects of radiotherapy on neovascular AMD.We searched CENTRAL, MEDLINE, Embase, LILACS and three trials registers and checked references of included studies. We last searched the databases on 4 May 2020. SELECTION CRITERIA: We included all randomised controlled trials in which radiotherapy was compared to another treatment, sham treatment, low dosage irradiation or no treatment in people with choroidal neovascularisation (CNV) secondary to AMD.We used standard procedures expected by Cochrane. We graded the certainty of the evidence using GRADE. We considered the following outcomes at 12 months: best-corrected visual acuity (BCVA) (loss of 3 or more lines, change in visual acuity), contrast sensitivity, new vessel growth, quality of life and adverse effects at any time point. MAIN RESULTS: We included 18 studies (n = 2430 people, 2432 eyes) of radiation therapy with dosages ranging from 7.5 to 24 Gy. These studies mainly took place in Europe and North America but two studies were from Japan and one multicentre study included sites in South America. Three of these studies investigated brachytherapy (plaque and epimacular), the rest were studies of external beam radiotherapy (EBM) including one trial of stereotactic radiotherapy. Four studies compared radiotherapy combined with anti-vascular endothelial growth factor (anti-VEGF) with anti-VEGF alone. Eleven studies gave no radiotherapy treatment to the control group; five studies used sham irradiation; and one study used very low-dose irradiation (1 Gy). One study used a mixture of sham irradiation and no treatment. Fifteen studies were judged to be at high risk of bias in one or more domains. Radiotherapy versus no radiotherapy There may be little or no difference in loss of 3 lines of vision at 12 months in eyes treated with radiotherapy compared with no radiotherapy (risk ratio (RR) 0.82, 95% confidence interval (CI) 0.64 to 1.04, 811 eyes, 8 studies, I2 = 66%, low-certainty evidence). Low-certainty evidence suggests a small benefit in change in visual acuity (mean difference (MD) -0.10 logMAR, 95% CI -0.17 to -0.03; eyes = 883; studies = 10) and average contrast sensitivity at 12 months (MD 0.15 log units, 95% CI 0.05 to 0.25; eyes = 267; studies = 2). Growth of new vessels (largely change in CNV size) was variably reported and It was not possible to produce a summary estimate of this outcome. The studies were small with imprecise estimates and there was no consistent pattern to the study results (very low-certainty evidence). Quality of life was only reported in one study of 199 people; there was no clear difference between treatment and control groups (low-certainty evidence). Low-certainty evidence was available on adverse effects from eight of 14 studies. Seven studies reported on radiation retinopathy and/or neuropathy. Five of these studies reported no radiation-associated adverse effects. One study of 88 eyes reported one case of possible radiation retinopathy. One study of 74 eyes graded retinal abnormalities in some detail and found that 72% of participants who had radiation compared with 71% of participants in the control group had retinal abnormalities resembling radiation retinopathy or choroidopathy. Four studies reported cataract surgery or progression: events were generally few with no consistent evidence of any increased occurrence in the radiation group. One study noted transient disturbance of the precorneal tear film but there was no evidence from the other two studies that reported dry eye of any increased risk with radiation therapy. None of the participants received anti-VEGF injections. Radiotherapy combined with anti-VEGF versus anti-VEGF alone People receiving radiotherapy/anti-VEGF were probably more likely to lose 3 or more lines of BCVA at 12 months compared with anti-VEGF alone (RR 2.11, 95% CI 1.40 to 3.17, 1050 eyes, 3 studies, moderate-certainty). Most of the data for this outcome come from two studies of epimacular brachytherapy (114 events) compared with 20 events from the one trial of EBM. Data on change in BCVA were heterogenous (I2 = 82%). Individual study results ranged from a small difference of -0.03 logMAR in favour of radiotherapy/anti-VEGF to a difference of 0.13 logMAR in favour of anti-VEGF alone (low-certainty evidence). The effect differed depending on how the radiotherapy was delivered (test for interaction P = 0.0007). Epimacular brachytherapy was associated with worse visual outcomes (MD 0.10 logMAR, 95% CI 0.05 to 0.15, 820 eyes, 2 studies) compared with EBM (MD -0.03 logMAR, 95% CI -0.09 to 0.03, 252 eyes, 2 studies). None of the included studies reported contrast sensitivity or quality of life. Growth of new vessels (largely change in CNV size) was variably reported in three studies (803 eyes). It was not possible to produce a summary estimate and there was no consistent pattern to the study results (very low-certainty evidence). For adverse outcomes, variable results were reported in the four studies. In three studies reports of adverse events were low and no radiation-associated adverse events were reported. In one study of epimacular brachytherapy there was a higher proportion of ocular adverse events (54%) compared to the anti-VEGF alone (18%). The majority of these adverse events were cataract. Overall 5% of the treatment group had radiation device-related adverse events (17 cases); 10 of these cases were radiation retinopathy. There were differences in average number of injections given between the four studies (1072 eyes). In three of the four studies, the anti-VEGF alone group on average received more injections (moderate-certainty evidence).The evidence is uncertain regarding the use of radiotherapy for neovascular AMD. Most studies took place before the routine use of anti-VEGF, and before the development of modern radiotherapy techniques such as stereotactic radiotherapy. Visual outcomes with epimacular brachytherapy are likely to be worse, with an increased risk of adverse events, probably related to vitrectomy. The role of stereotactic radiotherapy combined with anti-VEGF is currently uncertain. Further research on radiotherapy for neovascular AMD may not be justified until current ongoing studies have reported their results." @default.
• W4254366380 created "2022-05-12" @default.
• W4254366380 creator A5050081586 @default.
• W4254366380 creator A5070533172 @default.
• W4254366380 creator A5089915832 @default.
• W4254366380 creator A5091162454 @default.
• W4254366380 date "2020-08-26" @default.
• W4254366380 modified "2023-09-26" @default.
• W4254366380 title "Radiotherapy for neovascular age-related macular degeneration" @default.
• W4254366380 cites W1501622666 @default.
• W4254366380 cites W1563630578 @default.
• W4254366380 cites W1586374613 @default.
• W4254366380 cites W1605716041 @default.
• W4254366380 cites W1684796264 @default.
• W4254366380 cites W1967652163 @default.
• W4254366380 cites W1970949526 @default.
• W4254366380 cites W1972406655 @default.
• W4254366380 cites W1975142028 @default.
• W4254366380 cites W1978129813 @default.
• W4254366380 cites W1983681903 @default.
• W4254366380 cites W1996606921 @default.
• W4254366380 cites W2005896104 @default.
• W4254366380 cites W2008991258 @default.
• W4254366380 cites W2014455666 @default.
• W4254366380 cites W2019636431 @default.
• W4254366380 cites W2020034636 @default.
• W4254366380 cites W2020612979 @default.
• W4254366380 cites W2021588099 @default.
• W4254366380 cites W2024695401 @default.
• W4254366380 cites W2027731601 @default.
• W4254366380 cites W2033711787 @default.
• W4254366380 cites W2037236392 @default.
• W4254366380 cites W2037506745 @default.
• W4254366380 cites W2046378706 @default.
• W4254366380 cites W2046391772 @default.
• W4254366380 cites W2067784945 @default.
• W4254366380 cites W2068082492 @default.
• W4254366380 cites W2079049784 @default.
• W4254366380 cites W2087412974 @default.
• W4254366380 cites W2091702472 @default.
• W4254366380 cites W2102029073 @default.
• W4254366380 cites W2102764666 @default.
• W4254366380 cites W2118920977 @default.
• W4254366380 cites W2119165958 @default.
• W4254366380 cites W2122259418 @default.
• W4254366380 cites W2129921882 @default.
• W4254366380 cites W2134048257 @default.
• W4254366380 cites W2153081819 @default.
• W4254366380 cites W2165399492 @default.
• W4254366380 cites W2168754612 @default.
• W4254366380 cites W2336464624 @default.
• W4254366380 cites W2416101182 @default.
• W4254366380 cites W2418330703 @default.
• W4254366380 cites W2419721336 @default.
• W4254366380 cites W2462291236 @default.
• W4254366380 cites W2519403553 @default.
• W4254366380 cites W2564900344 @default.
• W4254366380 cites W2626835548 @default.
• W4254366380 cites W2761604622 @default.
• W4254366380 cites W2809611453 @default.
• W4254366380 cites W3041211928 @default.
• W4254366380 cites W306750052 @default.
• W4254366380 cites W4230906879 @default.
• W4254366380 cites W4237441839 @default.
• W4254366380 cites W4240178088 @default.
• W4254366380 doi "https://doi.org/10.1002/14651858.cd004004.pub4" @default.
• W4254366380 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32844399" @default.
• W4254366380 hasPublicationYear "2020" @default.
• W4254366380 type Work @default.
• W4254366380 citedByCount "2" @default.
• W4254366380 countsByYear W42543663802021 @default.
• W4254366380 countsByYear W42543663802022 @default.
• W4254366380 crossrefType "journal-article" @default.
• W4254366380 hasAuthorship W4254366380A5050081586 @default.
• W4254366380 hasAuthorship W4254366380A5070533172 @default.
• W4254366380 hasAuthorship W4254366380A5089915832 @default.
• W4254366380 hasAuthorship W4254366380A5091162454 @default.
• W4254366380 hasBestOaLocation W42543663802 @default.
• W4254366380 hasConcept C118487528 @default.
• W4254366380 hasConcept C126322002 @default.
• W4254366380 hasConcept C141071460 @default.
• W4254366380 hasConcept C168563851 @default.
• W4254366380 hasConcept C197934379 @default.
• W4254366380 hasConcept C2776403814 @default.
• W4254366380 hasConcept C2777416452 @default.
• W4254366380 hasConcept C2778257484 @default.
• W4254366380 hasConcept C509974204 @default.
• W4254366380 hasConcept C71924100 @default.
• W4254366380 hasConcept C95190672 @default.
• W4254366380 hasConceptScore W4254366380C118487528 @default.
• W4254366380 hasConceptScore W4254366380C126322002 @default.
• W4254366380 hasConceptScore W4254366380C141071460 @default.
• W4254366380 hasConceptScore W4254366380C168563851 @default.
• W4254366380 hasConceptScore W4254366380C197934379 @default.
• W4254366380 hasConceptScore W4254366380C2776403814 @default.
• W4254366380 hasConceptScore W4254366380C2777416452 @default.
• W4254366380 hasConceptScore W4254366380C2778257484 @default.
• W4254366380 hasConceptScore W4254366380C509974204 @default.
• W4254366380 hasConceptScore W4254366380C71924100 @default.
• W4254366380 hasConceptScore W4254366380C95190672 @default.

• next